{
  "trial_id": "NCT04356404",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age \u2265 18 years old at the time of starting biological modifier therapies or at the time of recruitment",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Positive for anti-HBc OR Positive for anti-HBs and born before year 1988",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Known HBV carrier with HBsAg positive",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Concomitant HCV and/ or HIV infection",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Already on HBV anti-viral",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Refuse to consent",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Baseline ALT > 80 IU/ml",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "Patient has chronic HCV infection, but no evidence of HBV carrier status or concomitant infections. He is on treatment with IFN and RBV combination therapy.",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT04356404",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}